4.2 Editorial Material

Patient and parent oriented tools to assess health-related quality of life, activity of daily living and caregiver burden in SMA. Rome, 13 July 2019

Journal

NEUROMUSCULAR DISORDERS
Volume 30, Issue 5, Pages 431-436

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.nmd.2020.02.019

Keywords

-

Funding

  1. Biogen

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Clinical Neurology

Risdiplam in types 2 and 3 spinal muscular atrophy: A randomised, placebo-controlled, dose-finding trial followed by 24 months of treatment

Eugenio Mercuri, Giovanni Baranello, Odile Boespflug-Tanguy, Liesbeth De Waele, Nathalie Goemans, Janbernd Kirschner, Riccardo Masson, Elena S. Mazzone, Astrid Pechmann, Maria Carmela Pera, Carole Vuillerot, Silvia Bader-Weder, Marianne Gerber, Ksenija Gorni, Janine Hoffart, Heidemarie Kletzl, Carmen Martin, Tammy McIver, Renata S. Scalco, Wai Yin Yeung, Laurent Servais

Summary: The study demonstrated a twofold increase in SMN protein after treatment with risdiplam, suggesting its potential effectiveness in treating spinal muscular atrophy. Additionally, the safety profile of risdiplam supported the continuation of the pivotal Part 2 study.

EUROPEAN JOURNAL OF NEUROLOGY (2023)

Article Clinical Neurology

Prevalence of Spinal Muscular Atrophy in the Era of Disease-Modifying Therapies An Italian Nationwide Survey

Giorgia Coratti, Martina Ricci, Anna Capasso, Adele D'amico, Valeria Sansone, Claudio Bruno, Sonia Messina, Federica Ricci, Tiziana Mongini, Michela Coccia, Gabriele Siciliano, Elena Pegoraro, Mara Turri, Massimiliano Filosto, Giacomo Comi, Riccardo Masson, Lorenzo Maggi, Irene Bruno, Maria Grazia D'Angelo, Antonio Trabacca, Veria Vacchiano, Maria Donati, Isabella Simone, Lucia Ruggiero, Antonio Varone, Lorenzo Verriello, Angela Berardinelli, Caterina Agosto, Antonella Pini, Maria Antonietta Maioli, Luigia Passamano, Filippo Brighina, Nicola Carboni, Matteo Garibaldi, Riccardo Zuccarino, Delio Gagliardi, Sabrina Siliquini, Stefano Previtali, Domenica Taruscio, Stefania Boccia, Maria Carmela Pera, Marika Pane, Eugenio Mercuri

Summary: This study aimed to assess the prevalence of SMA and treatment prescription in Italy. An online survey was conducted, and data on 1255 SMA patients were collected. The majority of patients (85%) were receiving one of the available treatments.

NEUROLOGY (2023)

Article Otorhinolaryngology

Assessing Prevalence and Characteristics of Oro-bulbar Involvement in Children and Adults with SMA Type 2 and 3 Using a Multimodal Approach

Federica Trucco, Francesca Salmin, Andrea Lizio, Giorgia Coratti, Emilio Albamonte, Maria Chiara Frisoni, Luca Mauro, Elena Carraro, Giovanni Palazzo, Jessica Lops, Camilla Cattaneo, Susanna Pozzi, Jacopo Casiraghi, Alessandra Di Bari, Beatrice Berti, Giulia Stanca, Martina Ricci, Marika Pane, Chad Heatwole, Nuran Dilek, Eugenio Mercuri, Valeria Ada Sansone

Summary: This study found that bulbar and jaw muscles are impaired in SMA patients, leading to difficulties in mastication and swallowing. However, long-term treatment with nusinersen medication can help stabilize oro-bulbar function and improve these issues.

DYSPHAGIA (2023)

Article Clinical Neurology

Type I spinal muscular atrophy patients treated with nusinersen: 4-year follow-up of motor, respiratory and bulbar function

Marika Pane, Giorgia A. Coratti, Valeria Sansone, Sonia Messina, Michela Catteruccia, Claudio Bruno, Maria Sframeli, Emilio Albamonte, Marina Pedemonte, Noemi Brolatti, Irene Mizzoni, Adele D'Amico, Chiara Bravetti, Beatrice Berti, Concetta Palermo, Daniela Leone, Francesca Salmin, Roberto De Sanctis, Maria Carmela Pera, Marco Piastra, Orazio Genovese, Federica Ricci, Ilaria Cavallina, Riccardo Masson, Riccardo Zanin, Caterina Agosto, Eleonora Salomon, Irene Bruno, Andrea Magnolato, Enrico Bertini, Francesco Danilo Tiziano, Francesca Bovis, Eugenio Mercuri, Italian EAP Working Grp

Summary: This study reports the 4-year follow-up in type I SMA patients treated with nusinersen and the changes in motor, respiratory and bulbar function in relation to subtype, age and SMN2 copy number. The results show that nusinersen treatment significantly improves motor, respiratory and bulbar function in SMA patients. Changes in CHOP INTEND and HINE-II scores were associated with age, nutritional and respiratory status.

EUROPEAN JOURNAL OF NEUROLOGY (2023)

Article Medicine, General & Internal

2-Year Change in Revised Hammersmith Scale Scores in a Large Cohort of Untreated Paediatric Type 2 and 3 SMA Participants

Georgia Stimpson, Danielle Ramsey, Amy Wolfe, Anna Mayhew, Mariacristina Scoto, Giovanni Baranello, Robert Muni Lofra, Marion Main, Evelin Milev, Giorgia Coratti, Marika Pane, Valeria Sansone, Adele D'Amico, Enrico Bertini, Sonia Messina, Claudio Bruno, Emilio Albamonte, Elena Stacy Mazzone, Jacqueline Montes, Allan M. Glanzman, Zarazuela Zolkipli-Cunningham, Amy Pasternak, Tina Duong, Sally Dunaway Young, Matthew Civitello, Chiara Marini-Bettolo, John W. Day, Basil T. Darras, Darryl C. De Vivo, Richard S. Finkel, Eugenio Mercuri, Francesco Muntoni

Summary: The study investigates the motor function of participants with Spinal Muscular Atrophy (SMA) using the Revised Hammersmith Scale (RHS), and contextualizes the findings with the Hammersmith Functional Motor Scale-Expanded (HFMSE). The transitional group, including crawlers, standers, and walkers-with-assistance, shows the most significant decline in the RHS score over a year. The study highlights the importance of considering SMA type, motor function, and baseline RHS score in interpreting the change scores.

JOURNAL OF CLINICAL MEDICINE (2023)

Review Medicine, General & Internal

Measuring Fatigue and Fatigability in Spinal Muscular Atrophy (SMA): Challenges and Opportunities

Rafael S. Rodriguez-Torres, David Uher, Emma L. Gay, Giorgia Coratti, Sally Dunaway Young, Annemarie Rohwer, Robert Muni Lofra, Darryl C. De Vivo, Michio Hirano, Nancy W. Glynn, Jacqueline Montes

Summary: Fatigue is a common symptom of SMA, however, establishing associations between self-reported fatigue scales and patient performance has proven difficult. This review evaluates the various patient-reported fatigue scales applied in SMA and considers the limitations and advantages of each measure. The variable use of fatigue-related nomenclature has affected assessment of physical fatigue attributes. This review encourages the development of original patient-reported scales for assessing perceived fatigability and evaluating treatment response.

JOURNAL OF CLINICAL MEDICINE (2023)

Article Clinical Neurology

Development of an International SMA Bulbar Assessment for Inter-professional Administration

Sally Dunaway Young, Katlyn McGrattan, Emily Johnson, Marise van der Heul, Tina Duong, Merete Bakke, Ulla Werlauff, Amy Pasternak, Camilla Cattaneo, Katie Hoffman, Lavinia Fanelli, Anne Breaks, Kristen Allison, Giovanni Baranello, Richard Finkel, Giorgia Coratti, Robert Muni Lofra

Summary: An international multidisciplinary team developed a standardized assessment tool for evaluating oral intake and bulbar function in individuals with spinal muscular atrophy (SMA). Consensus was reached on key aspects including oral intake status, oral facial structure and motor strength, swallowing physiology, voice & speech, and fatigability.

JOURNAL OF NEUROMUSCULAR DISEASES (2023)

Article Clinical Neurology

Longitudinal Analysis of PUL 2.0 Domains in Ambulant and Non-Ambulant Duchenne Muscular Dystrophy Patients: How do they Change in Relation to Functional Ability?

Marika Pane, Giorgia Coratti, Claudia Brogna, Francesca Bovis, Adele D'Amico, Elena Pegoraro, Luca Bello, Valeria Sansone, Emilio Albamonte, Elisabetta Ferraroli, Elena Stacy Mazzone, Lavinia Fanelli, Sonia Messina, Michela Catteruccia, Gianpaolo Cicala, Martina Ricci, Silvia Frosini, Giacomo De Luca, Enrica Rolle, Roberto De Sanctis, Nicola Forcina, Giulia Norcia, Luigia Passamano, Alice Gardani, Antonella Pini, Giulia Monaco, Maria Grazia D'Angelo, Anna Capasso, Daniela Leone, Riccardo Zanin, Gian Luca Vita, Chiara Panicucci, Claudio Bruno, Tiziana Mongini, Federica Ricci, Angela Berardinelli, Roberta Battini, Riccardo Masson, Giovanni Baranello, Claudia Dosi, Enrico Bertini, Luisa Politano, Eugenio Mercuri

Summary: The study aimed to assess 24-month PUL changes in a large cohort of DMD patients and determine if domain changes occur more frequently in specific functional subgroups. The results showed that changes in total score and each domain were significant at 12 and 24 months for different functional ability subgroups. These findings suggest that patterns of changes should be considered when designing clinical trials.

JOURNAL OF NEUROMUSCULAR DISEASES (2023)

Article Medicine, General & Internal

Onasemnogene abeparvovec in spinal muscular atrophy : predictors of efficacy and safety in naive patients with spinal muscular atrophy and following switch from other therapies

Marika Pane, Beatrice Berti, Anna Capasso, Giorgia Coratti, Antonio Varone, Adele D'Amico, Sonia Messina, Riccardo Masson, Valeria Ada Sansone, Maria Alice Donati, Caterina Agosto, Claudio Bruno, Federica Ricci, Antonella Pini, Delio Gagliardi, Massimiliano Filosto, Stefania Corti, Daniela Leone, Concetta Palermo, Roberta Onesimo, Roberto De Sanctis, Martina Ricci, Ilaria Bitetti, Maria Sframeli, Claudia Dosi, Emilio Albamonte, Chiara Ticci, Noemi Brolatti, Enrico Bertini, Richard Finkel, Eugenio Mercuri

Summary: This study examines the efficacy and safety of onasemnogene abeparvovec (OA) for infants with Spinal Muscular Atrophy across a wide age and weight range. The results show that changes in motor function measured by CHOP-INTEND are influenced by baseline score and age at treatment. Adverse events are more common in older patients with higher weight. These findings provide prognostic factors for treatment selection.

ECLINICALMEDICINE (2023)

Article Clinical Neurology

Clinical Phenotype of Pediatric and Adult Patients With Spinal Muscular Atrophy With Four SMN2 Copies: Are They Really All Stable?

Martina Ricci, Gianpaolo Cicala, Anna Capasso, Giorgia Coratti, Stefania Fiori, Costanza Cutrona, Adele D'Amico, Valeria A. Sansone, Claudio Bruno, Sonia Messina, Tiziana Mongini, Michela Coccia, Gabriele Siciliano, Elena Pegoraro, Riccardo Masson, Massimiliano Filosto, Giacomo P. Comi, Stefania Corti, Dario Ronchi, Lorenzo Maggi, Maria G. D'Angelo, Veria Vacchiano, Chiara Ticci, Lucia Ruggiero, Lorenzo Verriello, Federica S. Ricci, Angela L. Berardinelli, Maria Antonietta Maioli, Matteo Garibaldi, Vincenzo Nigro, Stefano C. Previtali, Maria Carmela Pera, Eduardo Tizzano, Marika Pane, Francesco Danilo Tiziano, Eugenio Mercuri

Summary: This study provides an overview of the clinical phenotypes associated with 4 SMN2 copies. The results show variability in untreated patients, ranging from type II to type IV, with an overall reduction in functional scores as age increases. The risk of losing ambulation is significantly associated with SMA type, and women have a lower risk of losing ambulation compared to men.

ANNALS OF NEUROLOGY (2023)

Review Pediatrics

New therapies for spinal muscular atrophy: where we stand and what is next

Laura Antonaci, Maria Carmela Pera, Eugenio Mercuri

Summary: The natural history of spinal muscular atrophy has been significantly influenced by improved care standards and the availability of disease-modifying therapies. This paper aims to present the current therapeutic scenario and challenges associated with new phenotypes emerging years after the introduction of therapies. It also includes a review of real-world data, offering insights into the safety and effectiveness of the drugs beyond clinical trials. The paper emphasizes future perspectives, including ongoing clinical trials and advancements in the use of available drugs.

EUROPEAN JOURNAL OF PEDIATRICS (2023)

No Data Available